Terapia inmunológica para el SIDA

Autores/as

  • Salvador B. Valdovinos Chávez Instituto Mexicano del Seguro Social-Nuevo León

Resumen

Los enfoques farmacológico e inmunológico para nuevas
intervenciones en la infección por VIH han llevado a
analizar el efecto alentador de nuevos agentes y a la
combinación potencial de los mismos. El reto es definir
cuales estrategias pueden resultar en beneficios clínicos de
largo plazo con un mínimo de toxicidad. El papel de la
terapia inmunológica debe ser cuidadosamente entendido
en el ámbito continuamente cambiante de los nuevos
medicamentos antirretrovirales

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Senior K. 1999, New drug makes host cell machinery unavailable to HIV. Mol Med Today;

:234-5.

Kiessling R, G Pawelec, RM Welsh, JD Barry, S Ferrone. Have tumor cells learnt from

microorganism how to fool the immune system? Mol Med Today 2000; 6:344-6.

Alcami A, UH Koszinowski. 2000, Viral mechanisms of immune evasion. Mol Med Today; 6:365-

Tortorella D, BE Gewurz, MH Furman, DJ Schust, HL Ploegh, 2000. Viral subversion of the

immune system. Annu Rev Immunol.; 18:861-926.

Kiessling, op. cit.

Idem

Tortorella, op.cit.

Kalvakolanu DV. 1999, Virus interception of cytokine-regulated pathways. Trends Microbiol;

:166-71.

Goodbourn S, 2000. Interferons: Cell signaling, immune modulation, antiviral responses and

virus countermeasures. J Gen Virol; (en prensa).

Mahr JA, LR Gooding. 1999 Immune evasion by adenoviruses. Immunol Rev; 168:121-30.

Albini A, S Ferrini, R Benelli, S Sforzini, D Giunciuglio, MG Aluigi, AE Proudfoot, S Alouani, TN

Wells, G Mariani, RL Rabin, JM Farber, DM Noonan 1998. HIV-1 Tat protein mimicry of

chemokines. Proc Nat Acad Sci USA; 95:13153-8.

Tortorella, op.cit

Spriggs MK. 1996. One step ahead of the game: viral immunomodulatory molecules. Annu

Rev Immunol; 14:101-30.

Fruh K, A Gruhler, RM Krishna, GJ Schoenhals 1999. A comparison of viral immune escape

strategies targeting the MHC class I assembly pathway. Immunol Rev; 168:157-66.

Farell HE, NJ Davis-Poynter 1998. From sabotage to camouflage: Viral evasion of cytotoxic T

lymphocyte and natural killer cell-mediated immunity. Sem Cell Dev Biol.; 9:369-78. 16. Plemper

RK, DH Wolf 1999. Retrograde protein translocation: Erradication of secretory proteins in health

and disease. Trends Biochem Sci; 24:266-70.

Moss RB, W Giermakowska, MR Wallace, J.R. Savary, F. C. Jensen, D. J. Carlo 2000. Cellmediated

immune responses to autologous virus in HIV-1 seropositive individuals after treatment

with the HIV-1 immunogen (REMUNE). (Abstract 583) 40th Interscience Conference on

Antimicrobial Agents and Chemotherapy, Toronto. American Society for Microbiology, 292.

Moss RB, J Diveley, E Gouveia, F.C.Jensen, D.J. Carlo, 2000. HIV-specific immune

responses are generated with a combination of gp120-depleted, whole-killed HIV-1 immunogen

with CpG immunostimulatory sequences of DNA. (Abstract: 584).40th Interscience Conference on

antimicrobial agents and chemotherapy, Toronto. American Society for Microbiology, 292.

Luscher MA, L Matukas, B Livingstone, a. Setter, R. Kaul, J. Kimani, P. Kiama j.j. Byayo, F.A.

Plummer, K. S. Macdonalds. Immunogenicity of conserved HIV-1 epitopes restricted by HLA

supertypes associated with resistance to HIV-1 infection among sex workers: significance for

vaccine design. (Abstract: 581). 40th Interscience Conference on Antimicrobial Agents and

Chemotherapy, Toronto. American Society for Microbiology, 291.

Borysiewicz LK. 2000; Laboratory techniques for measurement of T cell responses to viruses.

(Abstract: 2088). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy,

Toronto. American Society for Microbiology, 547.

Phillips RE, 2000. Evasion of early immune responses by persistent viruses: Lessons from

HCV and HIV. (Abstract: 2091). 40th Interscience Conference on Antimicrobial Agents and

Chemotherapy, Toronto. American Society for Microbiology, 547.

Moss (17)

Kahn J, S Lagakos, K Mayer, H Murray. A 1999; randomized, placebo controlled multicenter

study of Remune in subjects with 300-550 CD4 cells and unrestricted anti-retroviral

treatments. (Abstract: LB-21) 39th Interscience Conference on Antimicrobial Agents and

Chemotherapy, San Francisco. American Society for Microbiology.

Koup RA, JT Safrit, Y Cao, CA Andrews ,G McLeod, W Bokowsky, C Farthing, DD Ho

Temporal association of cellular immune responses with initial control of viremia in primary

HIV-1 syndrome. J Virol; 68:4650-5.

Safrit JT, CA Andrews, T Zhu, DD Ho, RA Koup 1994. Characterization of HIV-1 specific

cytotoxic T lymphocyte clones isolated during acute seroconversion: recognition of autologous

virus sequences within conserved immunodominant epitope. J Exp Med; 179:463-72.

Luzuria K, RA Koup, CA Pikora, DB Brettler, JL Sullivan 1991. Deficient HIV-1 specific

cytotoxic T cell responses in vertically infected children. . J Pediatr; 119:230-6.

Pantaleo G, JF Demarest, H Soudeyns, C Graziosi , F. Denis , JW Adelsberger, P Borrow, MS

Saag, Shaw GM, Sekaly RP, Fauci AS. 1994. Major expansion of CD8+ T cells with predominant

Vb usage during the primary immune response to HIV. Nature; 370:463-7.

Safrit, op.cit.

Descargas

Publicado

2010-12-31

Cómo citar

Valdovinos Chávez, S. B. (2010). Terapia inmunológica para el SIDA. RESPYN Revista Salud Pública Y Nutrición, 1(4). Recuperado a partir de https://respyn.uanl.mx/index.php/respyn/article/view/54

Número

Sección

Artículo Original